AbbVie's current ratio is below 1 at around 0.81, which is weaker than the typical safety threshold of 1.5, indicating potential challenges covering short-term liabilities with current assets.

The quick ratio near 0.69 points to dependence on less liquid current assets and limited buffer without inventory, raising concerns about immediate liquidity in tight cash conditions.

Liquidity has been relatively stable but below optimal levels over recent quarters, showing no significant improvement and highlighting possible constraints on liquidity management.

Given the subpar liquidity ratios, there is a moderate risk of near-term cash flow pressure especially if unexpected demands or disruptions occur, though operational cash flow and credit access may partially mitigate this.

The negative debt-to-equity ratio reflects AbbVie's large accumulated negative equity largely due to goodwill and acquisition accounting, indicating a highly leveraged balance sheet uncommon but not unusual in pharma due to acquisitions.

With debt representing over 52% of total assets, AbbVie is significantly leveraged, exposing it to interest rate and refinancing risks especially under volatile capital markets.

Interest coverage above 8x suggests that AbbVie generates sufficient operating earnings to service its debt comfortably at present, though any material earnings pressure could impair this capacity.

Long-term financial health depends on sustaining strong earnings growth, managing refinancing needs prudently, and successful innovation to offset patent expirations and regulatory pricing challenges.

AbbVie’s beta is not directly provided here but given sector norms, it likely moves in line or modestly less volatile than the market, reflecting partial defensive characteristics of healthcare stocks.

The stock shows moderate volatility, supported by steady growth drivers but tempered by regulatory and patent risks, generally matching or slightly exceeding sector volatility due to pipeline uncertainties.

AbbVie is moderately sensitive to macro factors such as interest rates affecting debt costs, government drug pricing reforms, and broader economic cycles impacting healthcare spending patterns.

Successful commercialization of pipeline drugs and continued growth in Skyrizi and Rinvoq could materially boost revenues and earnings, supporting valuation upside toward or above current analyst price targets near $287 to $328 range.

Revenue erosion from biosimilar competition, unfavorable regulatory pricing impacts, pipeline failures, and legal/regulatory setbacks could materially depress earnings and share price, especially given leverage.

The current risk-reward balance is moderate; while the company offers growth potential, risks from financial leverage and external pressures warrant cautious investment sizing.

Investors should consider moderate allocation given the balanced risk profile, with ongoing monitoring of pipeline progress and regulatory developments critical for risk management.